M&T Bank Corp Takes $370.95 Million Position in Lantheus Holdings, Inc. $LNTH

M&T Bank Corp acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,518,444 shares of the medical equipment provider’s stock, valued at approximately $370,950,000. Lantheus comprises about 1.1% of M&T Bank Corp’s portfolio, making the stock its 13th largest holding. M&T Bank Corp owned about 0.08% of Lantheus at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. lifted its holdings in shares of Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares in the last quarter. First Horizon Corp purchased a new stake in shares of Lantheus in the third quarter valued at $26,000. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus in the second quarter valued at $36,000. Farther Finance Advisors LLC lifted its holdings in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lantheus in the third quarter valued at $55,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. JonesTrading lowered Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Truist Financial increased their price objective on Lantheus from $89.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, April 15th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research note on Tuesday, February 24th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.86.

Lantheus Trading Down 2.9%

Shares of NASDAQ:LNTH opened at $81.57 on Wednesday. The stock has a market capitalization of $5.31 billion, a PE ratio of 24.20 and a beta of -0.12. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $108.91. The firm has a fifty day moving average price of $77.03 and a 200 day moving average price of $66.73. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The firm had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. Lantheus’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts expect that Lantheus Holdings, Inc. will post 4.29 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.